Avacta and Pall broaden drug discovery analysis partnership
This article was originally published in Clinica
UK pharmaceutical and diagnostic services firm Avacta is teaming up with US filtration, separation and purification specialist Pall to provide analytical services to pharma companies, particularly in North America. They believe they can reduce the costs of drug discovery by screening molecules early in the development process to determine their functional properties, as well as optimising manufacturing and purification conditions.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.